Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Care Professionals: A Randomized Clinical Trial

Alene Kennedy-Hendricks, Emma E McGinty, Amber Summers, Susan Krenn, Michael I Fingerhood, Colleen L Barry, Alene Kennedy-Hendricks, Emma E McGinty, Amber Summers, Susan Krenn, Michael I Fingerhood, Colleen L Barry

Abstract

Importance: Stigma toward people with opioid use disorder (OUD) is pervasive in clinical settings, impeding delivery of high-quality care. To date, no study has evaluated the effect of different stigma-reduction messages or messengers among health care professionals.

Objective: To evaluate the effect of OUD-related messages delivered by different messengers on stigma and attitudes toward people with OUD among health care professionals.

Design, setting, and participants: This randomized clinical trial examined the effects of OUD-related messages delivered by a visual campaign alone or in combination with a written narrative vignette from the perspective of 1 of 3 messengers. Health care professionals in the US were recruited from 2 national online survey panels (Ipsos KnowledgePanel and SurveyHealthcareGlobus). A total of 1842 participants completed a web-based survey measuring stigma toward people with OUD from November 13 to 30, 2020.

Interventions: Eight groups were exposed to 1 of 2 message frames. One frame (Words Matter) emphasized the harm of stigmatizing language, and the other (Medication Treatment Works) focused on the effectiveness of medications approved by the US Food and Drug Administration for the treatment of OUD. Message frames were communicated through either a visual campaign alone or a visual campaign in combination with a written narrative vignette from the perspective of a simulated patient with OUD, a clinician, or a health care system administrator.

Main outcomes and measures: Dimensions of stigma toward people with OUD were measured on 5-point Likert scales that included items about desire for social distance from people with OUD, perception of individual blame for OUD, perspective of OUD as a medical condition, and support for increased governmental spending on OUD treatment. The level of warmth felt toward people with OUD was measured by a feeling thermometer (range, 0-100 points).

Results: Among 1842 participants, the mean (SD) age was 47 (13) years; 1324 participants (71.9%) were female, 145 (7.9%) were Hispanic, 140 (7.6%) were non-Hispanic Black, 1344 (73.0%) were non-Hispanic White, and 213 (11.6%) were of other non-Hispanic race (ie, individuals who did not self-report race as Black or White and did not self-report ethnicity as Hispanic). Compared with nonexposure, exposure to the combination of visual campaign and narrative vignette communicating the importance of nonstigmatizing language from the perspective of a patient with OUD was associated with a lower probability (difference, -16.8 percentage points, 95% CI, -26.1 to -7.4; P < .001) of unwillingness to have a person with OUD marry into the family (a measure of social distance preference) and a 7.2-point (95% CI, 3.2-11.1; P < .001) higher warmth rating. Participants exposed to the combined visual campaign and patient vignette about the value of medication treatment for OUD also had significantly lower levels of stigma compared with those in the nonexposed control group (eg, unwillingness to have a person with OUD as a neighbor: difference, -15.3 percentage points; 95% CI, -24.6 to -6.0; P = .001).

Conclusions and relevance: In this study, messages about nonstigmatizing language and effective medication for OUD reduced stigma among health care professionals. Stigma-reduction efforts targeting health care professionals may improve health care system capacity to serve people with OUD.

Trial registration: ClinicalTrials.gov Identifier: NCT05127707.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Kennedy-Hendricks reported receiving grants from Johns Hopkins Bloomberg School of Public Health during the conduct of the study and grants from Arnold Ventures, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse outside the submitted work. Dr McGinty reported receiving grants from Arnold Ventures, the Centers for Disease Control and Prevention, the National Institute of Mental Health, and the National Institute on Drug Abuse outside the submitted work. No other disclosures were reported.

Figures

Figure.. CONSORT Flow Diagram
Figure.. CONSORT Flow Diagram
aExcluded if not working in health care profession at time of study. Nurses, physicians categorized as general practitioners or family doctors, and physicians categorized as specialists were included to achieve 600 participants, with approximately one-third represented from each category. bExcluded if not working in health care profession at time of study or if working in a nonqualifying health care profession, such as dentist, dental hygienist, dental assistant, optometrist, veterinarian, veterinary assistant, or massage therapist. cIpsos KnowledgePanel used a probability proportional to size sampling approach to select 9 random samples.

References

    1. Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiatry. 2021;78(5):562-564. doi:10.1001/jamapsychiatry.2020.4218
    1. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2021. Accessed February 7, 2021.
    1. Volkow ND. Stigma and the toll of addiction. N Engl J Med. 2020;382(14):1289-1290. doi:10.1056/NEJMp1917360
    1. McGinty EE, Barry CL. Stigma reduction to combat the addiction crisis—developing an evidence base. N Engl J Med. 2020;382(14):1291-1292. doi:10.1056/NEJMp2000227
    1. Tsai AC, Kiang MV, Barnett ML, et al. . Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969. doi:10.1371/journal.pmed.1002969
    1. Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol. 2001;27:363-385. doi:10.1146/annurev.soc.27.1.363
    1. Morone JA. Enemies of the people: the moral dimension to public health. J Health Polit Policy Law. 1997;22(4):993-1020. doi:10.1215/03616878-22-4-993
    1. Kim JW, Morgan E, Nyhan B. Treatment versus punishment: understanding racial inequalities in drug policy. J Health Polit Policy Law. 2020;45(2):177-209. doi:10.1215/03616878-8004850
    1. van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1-2):23-35. doi:10.1016/j.drugalcdep.2013.02.018
    1. Kulesza M, Larimer ME, Rao D. Substance use related stigma: what we know and the way forward. J Addict Behav Ther Rehabil. 2013;2(2):782. doi:10.4172/2324-9005.1000106
    1. Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. Subst Abus. 2020;41(4):519-525. doi:10.1080/08897077.2019.1671942
    1. Mendiola CK, Galetto G, Fingerhood M. An exploration of emergency physicians’ attitudes toward patients with substance use disorder. J Addict Med. 2018;12(2):132-135. doi:10.1097/ADM.0000000000000377
    1. Goddu AP, O’Conor KJ, Lanzkron S, et al. . Do words matter? stigmatizing language and the transmission of bias in the medical record. J Gen Intern Med. 2018;33(5):685-691. doi:10.1007/s11606-017-4289-2
    1. Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health–oriented policies. Psychiatr Serv. 2017;68(5):462-469. doi:10.1176/appi.ps.201600056
    1. McGinty E, Pescosolido B, Kennedy-Hendricks A, Barry CL. Communication strategies to counter stigma and improve mental illness and substance use disorder policy. Psychiatr Serv. 2018;69(2):136-146. doi:10.1176/appi.ps.201700076
    1. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? a randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202-207. doi:10.1016/j.drugpo.2009.10.010
    1. Ashford RD, Brown AM, Curtis B. Substance use, recovery, and linguistics: the impact of word choice on explicit and implicit bias. Drug Alcohol Depend. 2018;189:131-138. doi:10.1016/j.drugalcdep.2018.05.005
    1. Ashford RD, Brown AM, Curtis B. The language of substance use and recovery: novel use of the go/no-go association task to measure implicit bias. Health Commun. 2019;34(11):1296-1302. doi:10.1080/10410236.2018.1481709
    1. McGinty EE, Stone EM, Kennedy-Hendricks A, Barry CL. Stigmatizing language in news media coverage of the opioid epidemic: implications for public health. Prev Med. 2019;124:110-114. doi:10.1016/j.ypmed.2019.03.018
    1. Kelly JF, Wakeman SE, Saitz R. Stop talking ‘dirty’: clinicians, language, and quality of care for the leading cause of preventable death in the United States. Am J Med. 2015;128(1):8-9. doi:10.1016/j.amjmed.2014.07.043
    1. Dell Medical School . Reducing stigma education tools (ReSET). Dell Medical School, The University of Texas at Austin. July 21, 2020. Accessed March 25, 2021.
    1. Grayken Center for Addiction . Reducing stigma: why words about addiction matter. Boston Medical Center; 2021. Accessed March 25, 2021.
    1. Kennedy-Hendricks A, McGinty EE, Barry CL. Effects of competing narratives on public perceptions of opioid pain reliever addiction during pregnancy. J Health Polit Policy Law. 2016;41(5):873-916. doi:10.1215/03616878-3632230
    1. Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269-1272. doi:10.1176/appi.ps.201400140
    1. McGinty EE, Goldman HH, Pescosolido B, Barry CL. Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. Soc Sci Med. 2015;126:73-85. doi:10.1016/j.socscimed.2014.12.010
    1. McGinty EE, Stone EM, Kennedy-Hendricks A, Bachhuber MA, Barry CL. Medication for opioid use disorder: a national survey of primary care physicians. Ann Intern Med. 2020;173(2):160-162. doi:10.7326/M19-3975
    1. Mancher M, Leshner AI, eds. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019.
    1. Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder—and its treatment. JAMA. 2014;311(14):1393-1394. doi:10.1001/jama.2014.2147
    1. Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis—buprenorphine myths and realities. N Engl J Med. 2018;379(1):1-4. doi:10.1056/NEJMp1802741
    1. Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627. doi:10.1016/j.drugalcdep.2021.108627
    1. Kennedy-Hendricks A, Barry CL, Stone E, Bachhuber MA, McGinty EE. Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians. Drug Alcohol Depend. 2020;216:108217. doi:10.1016/j.drugalcdep.2020.108217
    1. Heley K, Kennedy-Hendricks A, Niederdeppe J, Barry C. Reducing health-related stigma through communication approaches. Health Commun. 2019:1-12.
    1. Ipsos Group . KnowledgePanel: a methodological overview. Ipsos Group. Accessed November 1, 2020.
    1. SurveyHealthcareGlobus. Panel counts. SurveyHealthcareGlobus; 2020. Accessed November 1, 2020.
    1. Pescosolido BA, Martin JK, Long JS, Medina TR, Phelan JC, Link BG. “A disease like any other”? a decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am J Psychiatry. 2010;167(11):1321-1330. doi:10.1176/appi.ajp.2010.09121743
    1. Link BG, Phelan JC, Bresnahan M, Stueve A, Pescosolido BA. Public conceptions of mental illness: labels, causes, dangerousness, and social distance. Am J Public Health. 1999;89(9):1328-1333. doi:10.2105/AJPH.89.9.1328
    1. Corrigan PW, Green A, Lundin R, Kubiak MA, Penn DL. Familiarity with and social distance from people who have serious mental illness. Psychiatr Serv. 2001;52(7):953-958. doi:10.1176/appi.ps.52.7.953
    1. Nelson SC. Feeling thermometer. In: Lavrakas PJ, ed. Encyclopedia of Survey Research Methods. Vol 1. Sage Publications; 2008:276.
    1. Blendon RJ, Benson JM. The public and the opioid-abuse epidemic. N Engl J Med. 2018;378(5):407-411. doi:10.1056/NEJMp1714529
    1. Anderson ML. Multiple inference and gender differences in the effects of early intervention: a reevaluation of the Abecedarian, Perry Preschool, and Early Training projects. J Am Stat Assoc. 2008;103(484):1481-1495. doi:10.1198/016214508000000841
    1. Meisel ZF, Metlay JP, Sinnenberg L, et al. . A randomized trial testing the effect of narrative vignettes versus guideline summaries on provider response to a professional organization clinical policy for safe opioid prescribing. Ann Emerg Med. 2016;68(6):719-728. doi:10.1016/j.annemergmed.2016.03.007
    1. Department of Behavioral Health and Intellectual Disability Services. Bupe works. City of Philadelphia; 2021. Accessed March 25, 2021.
    1. NYC Health . Living proof campaign. Government of New York City; 2019. Accessed March 25, 2021.
    1. Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: what role does stigma play? Subst Abus. 2019;40(4):459-465. doi:10.1080/08897077.2019.1640833
    1. Day JC, Christnacht C. Women hold 76% of all health care jobs, gaining in higher-paying occupations. United States Census Bureau. August 14, 2019. Accessed December 11, 2021.

Source: PubMed

3
Tilaa